Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Pharmaceutical Business Review
Return to: PBR Home
Latest White Papers
Sign up to NNIT’s Newsletter
| By NNIT
Sign up to NNIT’s newsletter and receive inspiration on how IT can create value for life sciences companies. You'll get articles, whitepapers, cases and invitations to webinars. Sign up here: http://www.nnit.com/pages/news.aspx#/
White Papers
Exosomes and Microvesicles: Characterisation by Nanoparticle Tracking Analysis
| By Malvern Instruments
While the principles underpinning the Nanoparticle Tracking Analysis (NTA) technique have been described in an earlier white paper, it must be reiterated that the use of high intensity laser beams combined with a low-background optical configuration allows particles of deeply sub-micron dimensions to be visualised, the lower range of particle sizes measureable depending on particle refractive index.
White Papers
Viruses and Viral Vaccines: Characterisation by Nanoparticle Tracking Analysis
| By Malvern Instruments
NTA utilises the properties of both light scattering and Brownian motion in order to obtain the particle size distribution of samples in liquid suspension. A laser beam is passed through the sample chamber, and the particles in suspension in the path of this beam scatter light in such a manner that they can easily be visualised via a 20x magnification microscope onto which is mounted a camera. The camera, which operates at approximately 30 frames per second (fps), captures a video file of the particles moving under Brownian motion within the field of view of approximately 100μm x 80 μm x 10 μm (Figure 1).
White Papers
How can Nanoparticle Tracking Analysis Assist in the Production of Nanoparticles
| By Malvern Instruments
This white paper highlights the growth in the use of the technique of Nanoparticle Tracking Analysis as applied to nanoparticles and nanomaterials production and analysis, from the very first reports on nanoscale silver and gold (Lundahl et al. (2008) and Marsh et al. (2008), respectively).
White Papers
Ophthalmic Study Endpoints
| By Cromsource
Ophthalmic studies rely on complex tests and assessments to meet clinical study endpoints. Each test may be time-consuming to administer, assess, and interpret. Consequently, it is important not to overcrowd a study with unnecessary assessments. Choosing endpoints that are clinically relevant is increasingly important in bringing new therapies to market more quickly.This paper provides a brief overview of some common endpoints in ophthalmology research, and issues to take into account when considering endpoints for ophthalmic studies.
White Papers
Ophthalmology Site Selection
| By Cromsource
Ophthalmology studies use cutting edge technologies and highly technical endpoints. Many assessments involve an understanding of physics and the standardisation of tests across study sites is crucial. Sites must be able to demonstrate that they have excellent experience in managing and conducting ophthalmic research.This paper provides a brief overview of the site selection process and highlights points for consideration when selecting study sites for ophthalmic research.
White Papers
Ophthalmology Site Certification
| By Cromsource
Ophthalmology studies employ technical endpoints requiring specialised capabilities and a detailed understanding of ophthalmic research methods. Correct implementation of the study protocol and consistency of data across sites may be achieved by ensuring that sites and personnel are trained to a high standard and will deploy testing in a consistent manner. Site certification is an important tool used to standardise procedures and add credibility to clinical study data.This paper provides a brief overview of points to consider in site certification for ophthalmology studies.
White Papers
Global Biosimilar Development
| By PRA Health Sciences
Many different terms are used in different parts of the world to describe “biosimilar products.” It is important to understand and differentiate true biosimilars from others because of the potential concern for patient safety and efficacy, and the misconceptions that can arise from misleading published reports.
White Papers
Global Capabilities in Central Nervous System Research
| By PRA Health Sciences
PRA Health Sciences’ (PRA) Early Development Services (EDS) group has a long-standing track record of early clinical development work in various CNS indications through our global clinical facilities.
White Papers
Cystic Fibrosis: Pulmonary Aspects of the Disease
| By Cromsource
Cystic fibrosis (CF) is a genetic disease which is usually caused by the absence, dysfunction or reduced number of the multifunctional CF transmembrane regulator (CFTR) protein... Recently new therapy approaches such as ivacaftor have emerged which target the cause of the condition itself. This white paper focusses only on the current treatment of pulmonary complications of CF.
White Papers
See all White Papers